Free tool
FAERS Monitor: Advil Allergy and Congestion Relief
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022113 or its brand name (Advil Allergy and Congestion Relief, Chlorpheniramine Maleate, Ibuprofen, Phenylephrine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
576
Serious
31
5% of reports
Hospitalization
9
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective179
- product use in unapproved indication99
- drug effective for unapproved indication89
- somnolence50
- feeling abnormal28
- drug effect incomplete18
- therapeutic product effect incomplete18
- dizziness17
- therapeutic response unexpected16
- dyspnoea15
- fatigue14
- incorrect dose administered14
- abdominal pain upper11
- condition aggravated11
- malaise11
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 6 |
| 2013 | 44 |
| 2014 | 52 |
| 2015 | 114 |
| 2016 | 41 |
| 2017 | 17 |
| 2018 | 17 |
| 2019 | 34 |
| 2020 | 41 |
| 2021 | 44 |
| 2022 | 85 |
| 2023 | 59 |
| 2024 | 13 |
| 2025 | 6 |
| 2026 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,583 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug effective for unapproved indicationSignal | 89 | 111.3 | 91.9 | 9,601 |
| drug effect incompleteSignal | 18 | 18.1 | 11.5 | 274 |
| product use in unapproved indicationSignal | 99 | 14.6 | 12.2 | 1,254 |
| therapeutic response unexpectedSignal | 16 | 13.0 | 8.0 | 166 |
| therapeutic product effect incompleteSignal | 18 | 9.2 | 5.9 | 125 |
| somnolenceSignal | 50 | 9.1 | 7.0 | 354 |
| drug ineffectiveSignal | 179 | 5.0 | 4.4 | 599 |
| feeling abnormalSignal | 28 | 4.3 | 3.0 | 68 |
| incorrect dose administeredSignal | 14 | 2.2 | 1.3 | 8 |
| abdominal pain upper | 11 | 2.0 | 1.1 | 4 |
| condition aggravated | 11 | 1.3 | 0.7 | 1 |
| dizziness | 17 | 1.2 | 0.8 | 1 |
| dyspnoea | 15 | 1.0 | 0.6 | 0 |
| malaise | 11 | 0.9 | 0.5 | 0 |
| fatigue | 14 | 0.7 | 0.4 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.